Is Accelerate Diagnostics, Inc. overvalued or undervalued?

As of 3 August 2017, the valuation grade for Accelerate Diagnostics, Inc. moved from does not qualify to risky, indicating a deterioration in its financial standing. The company appears to be overvalued given its negative valuation ratios, including a Price to Book Value of -0.01 and an EV to Sales ratio of 4.11, which suggests that investors are paying a high price relative to the company's sales. Additionally, the EV to EBITDA ratio stands at -1.51, further highlighting the company's financial struggles.
In comparison to its peers, Accelerate Diagnostics, Inc. has a P/E ratio of 0.0000, while Clearpoint Neuro, Inc. has a P/E of -13.9815 and Stereotaxis, Inc. has a P/E of -11.2314, all indicating a challenging environment for companies in this sector. The stock has underperformed significantly, with a year-to-date return of -100.0% compared to the S&P 500's return of 12.22%, reinforcing the notion that the company is currently overvalued.